We’re on a mission!
At MY01, we envision a world where every disease is quantifiable and every patient receives precise, personalized care.
We develop innovative tools that measure previously unquantified diseases, connecting care teams to better patient outcomes. We deliver significant value to patients, providers, and payers through proactive monitoring and actionable insights. Our tools set the standard in compartment syndrome, and this is just the beginning.
Growing since
2015
Employees
40
Nationalities in Our Team
20
Degrees
64
Physician-Patient engagement is key to effective healthcare.
Healthcare is human.
Our founders
Edward Harvey, MDCM
Chief Medical Officer
Bio
Charles Allan, M.Eng
Chief Executive Officer
Bio
George Xereas, PhD
Founder
Bio
Timeline
March 2019
Company Incorporation
What started off as a Master’s project at McGill University, in March 2015, became an official startup as our founders: Charles, Ed, and George, officially registered the project as a corporate entity.
January 2020
CE Mark
MY01 receives positive notice from the European Commission to start selling our device across the European Union.
July 2020
FDA Clearance Granted
MY01 received its 510k clearance from the Food & Drug Administration (FDA) for its MY01 Continous Compartmental Pressure Monitor.
October 2021
Breakthrough Device Designation Granted
MY01 Inc. received its first-ever “Breakthrough Device” designation from the FDA, joining a select list of Orthopaedic companies to receive this designation since the program began in 2016.
December 2022
COTS Study
Completion of the clinical study surrounding the safety and functionality of MY01 in patients at risk for developing compartment syndrome. The trials were done in 6 sites across Canada from the largest level 1 trauma centers of the country.
April 2023
Quebec Study
The completion of the clinical study was used as a feasibility and safety trial to establish a baseline for pressures and what should be pressure triggers for surgical release (aka a fasciotomy).
April 2023
MY01 receives $12.5M USD in Funding
The Series A funding round, led by Investissement Quebec along with Desjardins Capital and Fondaction, was raised to expand commercialization activities in the United States and accelerate growth.
September 2023
1K Devices Milestone
The MY01 sets the gold standard for aiding in diagnosing compartment syndrome by surpassing a 1000 case milestone which highlights its vital role in enhancing clinical assessments.